- Home
- ACHL vs ESLA Comparison
ACHL vs ESLA Comparison
Compare ACHL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- ESLA
- Stock Information
- Founded
- ACHL 2016
- ESLA 2021
- Country
- ACHL United Kingdom
- ESLA United States
- Employees
- ACHL N/A
- ESLA N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHL Health Care
- ESLA Health Care
- Exchange
- ACHL Nasdaq
- ESLA Nasdaq
- Market Cap
- ACHL 40.4M
- ESLA 41.6M
- IPO Year
- ACHL 2021
- ESLA N/A
- Fundamental
- Price
- ACHL $1.07
- ESLA $0.82
- Analyst Decision
- ACHL Hold
- ESLA
- Analyst Count
- ACHL 3
- ESLA 0
- Target Price
- ACHL $2.83
- ESLA N/A
- AVG Volume (30 Days)
- ACHL 126.9K
- ESLA 15.4K
- Earning Date
- ACHL 11-14-2024
- ESLA 11-19-2024
- Dividend Yield
- ACHL N/A
- ESLA N/A
- EPS Growth
- ACHL N/A
- ESLA N/A
- EPS
- ACHL N/A
- ESLA N/A
- Revenue
- ACHL N/A
- ESLA N/A
- Revenue This Year
- ACHL N/A
- ESLA N/A
- Revenue Next Year
- ACHL N/A
- ESLA N/A
- P/E Ratio
- ACHL N/A
- ESLA N/A
- Revenue Growth
- ACHL N/A
- ESLA N/A
- 52 Week Low
- ACHL $0.63
- ESLA $0.63
- 52 Week High
- ACHL $1.76
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- ACHL 65.39
- ESLA 41.94
- Support Level
- ACHL $0.99
- ESLA $0.74
- Resistance Level
- ACHL $1.07
- ESLA $0.84
- Average True Range (ATR)
- ACHL 0.04
- ESLA 0.11
- MACD
- ACHL -0.00
- ESLA 0.01
- Stochastic Oscillator
- ACHL 80.31
- ESLA 37.53
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.